In this project we aim to develop small molecule drugs to promote the clearance of toxic material in the brain associated with Alzheimer's disease. Our drugs work by binding to a protein receptor on the surface of immune cells found in the brain. This receptor is genetically linked to Alzheimer's disease with high levels acting like a handbrake on the clearance of toxins by these immune cells. Our drugs act to reverse this action, effectively releasing the handbrake so the immune cells can do their work. The development of our small molecule drugs may lead to new therapeutic treatments to tackle Alzheimer’s disease.